The Epilepsy Bioinformatics Study for Antiepileptogenic Therapy (EpiBioS4Rx)

项目总结-EPIBIOS4RX总体 用于抗癫痫治疗的癫痫生物信息学研究(EpiBioS4Rx)，Cow在 对RFA-NS-16-012的反应，旨在通过以下方式促进抗癫痫疗法的发展 消除障碍，促进BASIC多学科团队的大规模协作研究 和临床神经学家，能够接触到广泛的患者群体，定义明确，严格标准化 动物模型和尖端分析方法。我们把我们的建议集中在抗癫痫治疗上。 创伤性脑损伤后的创伤性癫痫(PTE)，因为这种情况提供了最好的机会 确定患者致痫过程的发病时间。 EpiBioS4Rx的科学前提是：脑外伤后癫痫的发生可以通过特定的药物来预防 治疗；相关生物标记物的识别和严格的临床前试验的表现将 允许将来设计和实施经济上可行的全面临床试验 抗癫痫治疗。基于P20计划拨款的工作，我们的计划将包括 以下内容：(1)在我们的动物模型和患者中鉴定癫痫发生的生物标志物；(2)开发和利用 潜在抗癫痫(AEG)药物临床前试验的标准化平台，(3)识别一种或多种 未来介入临床试验的先导抗癫痫药物，(4)建立晚期脑外伤网络 有能力进行未来临床试验的中心，采用我们的主要抗癫痫药物 使用我们的生物标志物小组的个性化、基于医学的方法的背景，以及(5)开发和 纳入一项涉及消费者相互教育和合作的公共参与计划， 消费者组织和专业人士设计和执行未来的大规模介入临床试验 抗癫痫疗法。

PROJECT SUMMARY – EPIBIOS4RX OVERALL The Epilepsy Bioinformatics Study for Antiepileptogenic Therapy (EpiBioS4Rx), a CWOW proposal in response to RFA-NS-16-012, is designed to facilitate the development of antiepileptogenic therapies by removing barriers and promoting large-scale collaborative research efforts by multidisciplinary teams of basic and clinical neuroscientists with access to extensive patient populations, well-defined and rigidly standardized animal models, and cutting-edge analytic methodology. We focus our proposal on antiepileptogenesis in post- traumatic epilepsy (PTE) following traumatic brain injury (TBI), as this condition offers the best opportunity to determine the time of onset of the epileptogenic process in patients. The EpiBioS4Rx Scientific Premise is: Epileptogenesis after TBI can be prevented with specific treatments; the identification of relevant biomarkers and performance of rigorous preclinical trials will permit the future design and performance of economically feasible full-scale clinical trials of antiepileptogenic therapies. Based on the work from a P20 planning grant, our program will consist of the following: (1) identify biomarkers of epileptogenesis in our animal model and in patients, (2) Develop and utilize a standardized platform for preclinical trials of potential antiepileptogenic (AEG) drugs, (3) Identify 1 or more lead antiepileptogenic drugs for a future interventional clinical trial, (4) Establish a network of advanced TBI centers capable of carrying out future clinical trials featuring our lead antiepileptogenic drugs used in the context of a personalized, medicine-based approach utilizing our panel of biomarkers, and (5) Develop and incorporate a public engagement program involving the mutual education and collaboration of consumers, consumer organizations and professionals to design and execute future large-scale interventional clinical trials of antiepileptogenic therapies.